Skip to content
Politically.com Search all
Menu

2026 · 2nd Quarter (Apr 1 - June 30)

ALNYLAM PHARMACEUTICALS, INC.

Filed by ALNYLAM PHARMACEUTICALS, INC..

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
2nd Quarter - Report
Posted
Jul 20, 2026
Income
Not reported
Expenses
$450,000.00
Filing UUID
17780ebb-228e-4a40-b730-e60dcc381d66
Termination date
Not reported

Expense method: A

Literal source text

Lobbying issues and bill citations

PHA · Pharmacy

Implementation of The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (PL 116-94); issues related to drug pricing; FY2026 Labor HHS appropriations, issues related to genetically targeted technologies; HR1672, Maintaining Investments in New Innovation Act.

Literal federal measure citations: HR1672

MMM · Medicare/Medicaid

Issues related to the implementation of the Inflation Reduction Act; HR.4993, Joe Fiandra Access to Home Infusion Act; issues related to MFN drig pricing

Literal federal measure citations: HR.4993

TRD · Trade (domestic/foreign)

Issues relating to supply chain tariffs

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.